Project description
An automated microfluidic platform to screen ligands
Effective diagnostic technologies are essential for mitigating the devastating impact of infectious diseases. Identifying ligands that can target infectious disease biomarkers in patient samples is key to the function of modern diagnostics. However, current methods for ligand selection are slow and labour-intensive. Novel methods for automating ligand selection should increase the efficiency and capacity of communities to respond to disease outbreaks. The EU-funded microPhage project plans to develop a novel microfluidic device that could automate high-throughput ligand screening and apply it to generate novel ligands against an emerging HIV biomarker. The project will also explore novel microfluidic materials compatible with common ligand selection workflows.
Objective
Effective diagnostic technologies are essential for mitigating the devastating impact that infectious disease has on society. The identification of ligands that can target infectious disease biomarkers within patient samples is key to the function of modern diagnostics. Unfortunately, current methods for ligand selection are slow and labour intensive, and frequently hinder the development of diagnostic technologies. Novel methods for automating this process will increase efficiency and improve the capacity of communities to respond to outbreaks and epidemics. During this fellowship I will develop a novel microfluidic device capable of automated high-throughput selection of highly robust infectious disease targeting ligands. The main objectives are as follows: 1) Explore novel microfluidic materials that are compatible with common ligand selection work flows; 2) Develop a fully automated microfluidic platform capable of performing multiple rounds of ligand selection; 3) Apply this system to generate novel ligands against an emerging HIV biomarker. The device will be underpinned by multiple core microfluidic technologies developed within the host lab, including: rapid droplet generation, droplet disruption, non-fouling materials, and highly responsive microvalves. These technologies will be combined with my expertise in protein chemistry, protein engineering, and chemical biology to achieve a significant leap forwards in automated ligand selection. The resultant device will vastly increase accessibility to high-throughput ligand selection, enabling smaller labs to more effectively select high-affinity ligands against emerging disease targets. This will have a significant impact on the fields of diagnostics, targeted therapeutics, protein engineering, and microfluidics.
Fields of science
- natural sciencesphysical sciencesclassical mechanicsfluid mechanicsmicrofluidics
- natural sciencesbiological sciencesmicrobiologyvirology
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- engineering and technologymedical engineeringmedical laboratory technologydiagnostic technologies
Programme(s)
Funding Scheme
MSCA-IF-EF-ST - Standard EFCoordinator
8092 Zuerich
Switzerland